Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence.

Autor: Murvelashvili N; Department of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center, Dallas, Texas, USA., Xie L; University of Texas Health Science Center, School of Public Health, Dallas, Texas, USA.; Center for Pediatric Population Health, UT Health School of Public Health, Dallas, Texas, USA., Schellinger JN; Department of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center, Dallas, Texas, USA., Mathew MS; University of Texas Health Science Center, School of Public Health, Dallas, Texas, USA.; Center for Pediatric Population Health, UT Health School of Public Health, Dallas, Texas, USA., Marroquin EM; University of Texas Health Science Center, School of Public Health, Dallas, Texas, USA.; Center for Pediatric Population Health, UT Health School of Public Health, Dallas, Texas, USA., Lingvay I; Department of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center, Dallas, Texas, USA.; Peter O'Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, Texas, USA., Messiah SE; University of Texas Health Science Center, School of Public Health, Dallas, Texas, USA.; Center for Pediatric Population Health, UT Health School of Public Health, Dallas, Texas, USA.; Department of Pediatrics, John P. and Kathrine G. McGovern School of Medicine at UTHealth, Houston, Texas, USA., Almandoz JP; Department of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center, Dallas, Texas, USA.
Jazyk: angličtina
Zdroj: Obesity (Silver Spring, Md.) [Obesity (Silver Spring)] 2023 May; Vol. 31 (5), pp. 1280-1289. Date of Electronic Publication: 2023 Mar 30.
DOI: 10.1002/oby.23736
Abstrakt: Objective: The aim of this study was to compare the effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery (MBS) weight recurrence.
Methods: A retrospective analysis of 207 adults with post-MBS weight recurrence treated with semaglutide 1.0 mg weekly (n = 115) or liraglutide 3.0 mg daily (n = 92) at an academic center from January 1, 2015, through April 1, 2021, was conducted. The primary end point was percentage body weight change at 12 months of treatment with regimens containing semaglutide or liraglutide.
Results: The mean sample age was 55.2 years; mean BMI was 40.4 kg/m 2 ; 89.9% were female; and 50% completed sleeve gastrectomy, 29% completed Roux-en-Y gastric bypass, and 21% completed adjustable gastric banding. Least-squares mean weight change at 12 months was -12.92% versus -8.77% in the semaglutide and liraglutide groups, respectively (p < 0.001). The adjusted odds ratios were 2.34 (95% CI: 1.28-4.29) for ≥10% weight loss and 2.55 (95% CI: 1.22-5.36) for ≥15% weight loss over 12 months in the semaglutide group versus liraglutide group, respectively. Weight-loss efficacy of semaglutide (vs. liraglutide) did not differ by subgroups explored, including age, sex, and MBS procedure.
Conclusions: These results show that treatment regimens including semaglutide 1.0 mg weekly lead to superior weight loss compared with liraglutide 3.0 mg daily for treating post-MBS weight recurrence, regardless of procedure type or the magnitude of weight recurrence.
(© 2023 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society.)
Databáze: MEDLINE
Externí odkaz: